MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) — Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that Eugene A. Bauer, M.D., co-founder and chief medical officer of Dermira, has received a Presidential Citation from the American Academy of Dermatology (AAD). Dr. Bauer received the award at the Stars of the Academy Reception in Washington, D.C., which was held on March 3, 2016, during the annual meeting of the AAD.
“I am delighted to recognize the dedication and commitment of Dr. Eugene Bauer, whose lifetime of achievement in innovation through clinical research has resulted in significant contributions in the field of dermatology,” said Mark Lebwohl, M.D., president, American Academy of Dermatology 2015. “His research has led to innovations and new therapies which have advanced the practice of dermatology and the treatment of patients. Gene has dedicated his career to solving treatment challenges through new ideas while enriching the lives of others as a mentor and leader.”
“I cannot think of anyone more deserving of this award than my good friend and colleague, Gene Bauer,” said Tom Wiggans, chairman and chief executive officer of Dermira. “For many years, Gene’s intellect, determination and innovative work have inspired his peers, colleagues and the entire dermatology community. His adherence to placing patients above all else has earned him the trust and respect of all who interact with him.”
About the American Academy of Dermatology
The American Academy of Dermatology, founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 18,000 physicians worldwide, the AAD is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. For more information, please visit www.aad.org.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
CONTACT: Dermira Contact Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 investors@dermira.com Investor Contact Robert H. Uhl Managing Director Westwicke Partners 858.356.5932 robert.uhl@westwicke.com
